Skip to main content

Table 1 Characteristics of studies included in quantitative analysis

From: Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis

DiseaseAIHAMAHA
All studies
37 studies
1057 patients
24 studies
746 patients
13 studies
311 patients
 wAIHA
8 studies
182 patients
TTP
12 studies
297 patients
CAD
5 studies
173 patients
HUS
1 study
14 patients
Comparative studies
10 studies
297:405 patients
7 studies
232:303 patients
3 studies
65:102 patients
  1. Publication year: 2004–2018; sample size: 10–86 (mean age: 50.6, mean male proportion: 41.0%); rituximab regimen: 28 with 375 mg/m2 4 weekly, 8 with other regimen (e.g. 100 mg 4 weekly); study design: 13 clinical trials, 24 observational studies; 1st evaluation time: 0.2 months–1 year; follow-up time: 6–83 months